WASOG 2026

ILD Sessions

Bridging Rheumatology and Pulmonology: Advances in the Management of Connective Tissue Diseases (CTD)-Associated ILD

Imaging and Biomarkers in CTD-ILD: From Pattern Recognition to Precision Diagnosis
Early Detection for Better Outcomes: Who, When, and How to Screen
From Inflammation to Fibrosis: Insights into the Immunopathogenesis of CTD-ILD
CTD-ILD: What Truly Drives Outcomes – The Underlying Disease, Clinical Presentation, or Imaging Pattern?
Therapeutic Evolution in CTD-ILD: Integrating Immunomodulation and Antifibrotic Strategies
Systemic sclerosis-associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease
The Many Faces of Myositis-Associated Interstitial Lung Disease: From Autoantibodies to Phenotypes

Advances and Challenges in Hypersensitivity Pneumonitis

Idiopathic Pulmonary Fibrosis (IPF): From Mechanisms to Management

Controversial entities in Interstitial Lung Diseases

Bronchiolocentric Interstitial Pneumonia: A Distinct Entity? – Pro & Con
Rare Interstitial Pneumonias (AFOP, ACIF): Do They Deserve Separate Recognition? – Pro & Con
Interstitial Pneumonia with Autoimmune Features (IPAF): Still a Useful Concept? – Pro & Con
Management of Acute Exacerbations in Non-IPF ILD: Should the Approach Differ? – Pro & Con
New ERS/ATS International Multidisciplinary Classification of the Interstitial Pneumonias – Pro & Con

Detecting, Defining, and Managing Progression in Fibrotic Interstitial Lung Disease

Are We Getting It Right? The Challenge of Diagnosing Disease Progression in Fibrotic ILDs
From Pattern Recognition to Progression Assessment: Imaging Challenges in Fibrosis
The Many Faces of Progression: Phenotypic Diversity in Fibrotic ILDs
Can Histopathology Predict the Course of Fibrotic Lung Disease?
Slowing the Course: Current Approaches to Treating Progressive Fibrosis

Genetic and Familial Interstitial Lung Disorders

Familial Pulmonary Fibrosis: Clinical Implications and Therapeutic Options
Telomere-Related Genes: Can Pathogenic Variants Guide Prognosis?
No Genetic Variants Found — Should Our Approach to Familial Pulmonary Fibrosis Change?
Screening Family Members: Who, When, and How?

Rare and Challenging Diffuse Lung Disorders: New Trends and Novel Insights

Targeting the mTOR Pathway in Lymphangioleiomyomatosis: From Sirolimus to Next-Generation Therapeutics
Redefining Pulmonary Langerhans Cell Histiocytosis: From a Smoking-Related Disorder to a MAPK-Driven Neoplasia
Harnessing the GM-CSF Axis in Pulmonary Alveolar Proteinosis: From Whole-Lung Lavage to Targeted Immunotherapy
Beyond Corticosteroids: Precision B-Cell-Directed Therapy in IgG4-Related Lung Disease
Immune Dysregulation in Focus: Emerging Biomarkers and Biologic Therapies in Granulomatous Lymphocytic Interstitial Lung Disease
Olipudase Alfa and Beyond: The New Era of Enzyme Replacement Therapy in Acid Sphingomyelinase-Deficient Niemann-Pick Disease
Pleuroparenchymal Fibroelastosis: Unraveling the Enigma of Upper Lobe Fibrosis- Pathogenesis, Diagnosis, and Evolving Therapeutic Insights

Pulmonary Hypertension in Interstitial Lung Disease: Mechanisms, Markers, and Management

When Fibrosis Meets Vascular Disease: Pathogenic Pathways of Pulmonary Hypertension in ILD
Identifying PH in ILD: From Echocardiography to Right Heart Catheterization
Treating the Untreatable? Current and Emerging Therapies for PH-ILD
Recognizing and Managing Pulmonary Hypertension in CTD-Associated Interstitial Lung Disease
Pulmonary Hypertension in Sarcoidosis: Pathophysiology and Clinical Implications

Comprehensive Non-Pharmacologic Strategies in Fibrotic Interstitial Lung Disease

Pulmonary Rehabilitation and Exercise Training: Optimizing Capacity and Quality of Life in Fibrotic ILD
Oxygen Therapy and Non-Invasive Ventilatory Support: Bridging Hypoxemia and Comfort
Nutritional and Metabolic Support
Palliative and Supportive Care: Redefining Goals in Fibrotic Lung Disease
Lung Transplantation: The Final Frontier in Fibrotic ILD Management